Natco Pharma Limited CC-Jun24.pdf · 2024-08-13
Yes, hi. Good morning, and congratulations on the great momentum in terms of the numbers. So the question was, I mean in terms of the guidance, we've already done, say INR660 crores of PAT this quarter. Do we feel and are we being too greedy? But do we feel that because the rest of the year then kind of looks pretty much at par with last year, so do we feel that this guidance could be slightly conservative, and we would wish to overachieve?
Right. Yes, thank you. That's appreciated. And the previous participant asked about Kothur, but just from a more -- from a slightly higher perspective, is there any risks then, considering that you've mentioned that Revlimid is now la rgely move to Vizag. Then in that case, in case of anything adverse, which hopefully does not happen, but in case of any adverse regulations on Kothur, then do we have any severe risks then baked into the numbers?